Marshall Wace
IRD

Marshall Wace’s Opus Genetics IRD Stock Holding History

Marshall Wace’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8M Sell
1,945,609
-367,771
-16% -$1.72M 0.01% 1133
2026
Q1 		$10.5M Buy
2,313,380
+2,155,732
+1,367% +$7.46M 0.01% 955
2025
Q4 		$317K Buy
+157,648
New +$320K ﹤0.01% 2428
2021
Q3 		– Sell
-329,131
Closed -$1.74M – 3507
2021
Q2 		$1.74M Buy
+329,131
New +$1.63M 0.01% 1500

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace's IRD Position: Q2 2026 in Review

Marshall Wace reduced its Opus Genetics (IRD) stake by 16% in Q2 2026, selling an estimated $1.72M and leaving 1,945,609 shares worth $8M. The position accounts for 0.01% of the portfolio, ranked #1133.

Marshall Wace first reported a position in IRD in Q2 2021 and has held it in 4 quarters since. The position peaked at $10.5M in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Marshall Wace held 1,945,609 shares of Opus Genetics worth $8M as of Q2 2026.
  • Marshall Wace sold 367,771 Opus Genetics shares in Q2 2026, an estimated $1.72M.
  • Opus Genetics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1133 holding.
  • Marshall Wace first reported a position in Opus Genetics in Q2 2021 and has held it in 4 quarters since.
  • Marshall Wace's Opus Genetics position peaked at $10.5M in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.